Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
1,871.50
+1.50 (0.08%)
Nov 18, 2026, 3:28 PM IST
NSE:SUNPHARMA Revenue
Sun Pharmaceutical Industries had revenue of 161.99B INR in the quarter ending September 30, 2026, with 11.88% growth. This brings the company's total for the last twelve months to 616.31B, up 12.13% year-over-year. In the fiscal year ending March 31, 2026, Sun Pharmaceutical Industries had annual revenue of 584.62B with 11.19% growth. That makes Sun Pharmaceutical Industries the 2,142nd largest company in the world by revenue and 59th in India.
Revenue (ttm)
616.31B
Revenue Growth
+12.13%
P/S Ratio
7.29
Revenue / Employee
13.11M
Employees
47,000
Market Cap
4.49T
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full NSE:SUNPHARMA breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 584.62B | 58.84B | 11.19% |
| Mar 31, 2025 | 525.78B | 40.82B | 8.42% |
| Mar 31, 2024 | 484.97B | 46.11B | 10.51% |
| Mar 31, 2023 | 438.86B | 52.31B | 13.53% |
| Mar 31, 2022 | 386.54B | 51.56B | 15.39% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 369.13B |
| Zydus Lifesciences | 303.78B |
| Cipla | 279.89B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 156.32B |
| Mankind Pharma | 153.79B |
| Divi's Laboratories | 121.91B |
| Ipca Laboratories | 104.80B |
Sun Pharmaceutical Industries News
- 19 days ago - Sun Pharmaceutical Industries Transcript: Q2 26/27 - Transcripts
- 19 days ago - Sun Pharmaceutical Industries Quarterly report: Q2 2027 - Filings
- 19 days ago - Sun Pharmaceutical Industries Slides: Q2 2027 - Filings
- 19 days ago - India orders Sun Pharma to halt eye-care drug production at plant after quality lapses - Reuters
- 19 days ago - Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong - Reuters
- 19 days ago - Sun Pharma's Ilumya Wins FDA Approval For Active Psoriatic Arthritis - Nasdaq
- 26 days ago - Sun Pharma Reports Durable UNLOXCYT Responses In Advanced Skin Cancer - Nasdaq
- 4 weeks ago - Sun Pharma's UNLOXCYT Added As NCCN Category 2A Option For Locally Advanced Skin Cancer - Nasdaq